Monday, February 1, 2016

Unigold Inc. - UGD.v

Unigold Inc. - UGD.v is a Canadian-based, growth oriented, junior natural resource company focused on exploring and developing its gold projects in the Dominican Republic.

Unigold has been actively involved in exploration in the Dominican Republic for the past decade and is concentrated within the 75km-wide Cretaceous-age Tireo-formation volcano sedimentary rocks, known for hosting major deposits.

On February 1, 2016 the Company released News.

Unigold intersects 34.9 metres averaging 6.19 g/t Au with 0.6% Cu
Toronto, Ontario, February 1, 2016 – Unigold Inc. (“Unigold” or the “Company”) (TSX-UGD) is pleased to
announce that drilling at the Candelones Extension deposit, within the Company’s 100% owned Neita
Concession in the Dominican Republic, has expanded the massive sulphide mineralization initially reported
on January 25, 2016 and has identified a second massive sulphide zone below the initial discovery.
The massive sulphides are dominantly pyrite with lesser chalcopyrite. The first zone strikes northeast and
dips ten degrees south. Thickness varies from 5 metres on the edges (LP17) to over 30 metres in the center
(Ref. Table 1.0; LP15-95), defining a lenticular profile. The initial lens of massive sulphide has been traced 85
metres along strike and 75 metres down dip. It is discordant to lithology and open along strike and up dip
(Ref Figures 1.0 – 3.0). Results for the four holes to date are summarized in Table 1.0.
Table 1.0 – Massive Sulphide Mineralization – Candelones Extension
Hole From To Interval Au Cu True Width (1)
(m) (m) (m) (g/t) (%) (m)
LP15-93 298.6 314.3 15.7 7.45 1.1 14.0
LP15-95 252.6 287.5 34.9 6.19 0.6 32.0
and (2) 309.9 314.0 4.1 7.31 1.1 NA
LP15-96 279.0 313.0 34.0 4.15 0.4 31.0
and (2) 324.0 333.0 9.0 4.81 0.7 NA
No massive sulphide - truncated by faulting
(1) True width is estimated based on current interpretation of the attitude of the mineralization and the orientation.
On January 25, 2015 the company released News

Unigold Intersects 15.7 metres averaging 7.45 g/t Au with 1.1% Cu

Unigold Inc. (“Unigold” or the “Company”) (TSX-V:UGD) is pleased to announce results from ongoing exploration at the Company’s 100% owned Neita Concession in the Dominican Republic.

Exploration drilling testing potential high grade feeder zones at the Candelones Extension deposit commenced at “Target A” (Ref. Figure 1.0); evaluating a zone of massive sulphides intersected in late 2013 in hole LPMET-01 (6.93 g/t Au; 0.6% Cu / 22.0m). LP15-93 was designed to test 40 - 50 metres to the southwest of LPMET-01 and 40 - 50 metres above hole LP17 (6.05 g/t Au; 0.8% Cu / 6.0m. LP15-93 intersected a broad zone of stratabound mineralization that returned:
230.1 to 334.0 metres 103.9 metres(1) 2.09 g/t Au 0.3% Cu;
including a massive sulphide lens averaging:
298.6 to 314.3.0 metres 15.7 metres(2) 7.45 g/t Au 1.1% Cu;

(1) Interval is drilled length not true width. Hole orientation is perpendicular to mineralization, therefore the drilled length should approximate true width.
(2) Interval is drilled length not true width. There is insufficient data at this time to estimate true width.

Joseph Del Campo, Interim President and CEO of Unigold notes: “We are very excited with the results from the first hole of our winter exploration program. The discovery of a discordant lens of high grade massive sulphide within the broader, lower grade, stratabound mineralization previously drilled on 100 metre centers, demonstrates the potential we are attempting to capture with this targeted exploration program. This model, of higher grade feeder zones within a broader zone of lower grade mineralization, is consistent with other gold / copper deposits within the Tireo Formation of the Dominican Republic and we believe there is an excellent opportunity to increase the mineral resources at the Candelones Extension.”





By using the material on this blog you agree to all the terms of this disclaimer. You agree that the use of Penny Stock Journal is at your own risk. In no event will Penny Stock Journal be liable for any direct or indirect losses caused by any information on this site or on any linked site. The materials on the site are not an offer to sell or a solicitation of an offer to buy any security, nor shall any security be offered or sold to any person, in any jurisdiction in which such offer would be unlawful under the securities laws of such jurisdiction. Penny Stock Journal makes no representations, and specifically disclaims all warranties, express, implied, or statutory, regarding the accuracy, timeliness, or completeness of any material contained in this site. Penny Stock Journal cannot be held liable for the material contained herein. The principal of Penny Stock Journal may hold a position in any of the securities profiled on the site. Penny Stock Journal will not be responsible for reporting any changes to that position. Penny Stock Journal does not make investment recommendations. High risk stock speculation can result in large financial losses and is not suitable for some investors.

Thursday, January 28, 2016

Stellar Biotechnologies Inc - KLH.v

Stellar Biotechnologies Inc - KLH.v is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH).

KLH is an important immune-stimulating protein, highly valued in wide-ranging therapeutic and diagnostic markets. Stellar Biotechnologies revolutionized the KLH industry, turning this vital, natural protein into a renewable, quality resource.

(The KLH protein is potently immunogenic yet safe in humans and is therefore highly prized as a vaccine carrier protein.)

On January 20, 2016 the company released News

Stellar Biotechnologies, Inc. ("Stellar") (NASDAQ: SBOT) (TSX VENTURE: KLH) and Neovacs S.A. ("Neovacs") (ALTERNEXT PARIS: ALNEV) today announced they have entered into a term sheet to form a joint venture for the manufacture of conjugated therapeutic vaccines (the "Joint Venture") using Stellar's proprietary Keyhole Limpet Hemocyanin (KLH). The purpose of the proposed Joint Venture is to produce Neovacs' Kinoid product candidates, including IFNa-Kinoid, as well as potentially manufacture other KLH-based immunotherapies on behalf of third party customers.

The parties intend to negotiate the terms of one or more definitive agreements related to the organization, ownership allocation, and supply and services for the Joint Venture. The parties anticipate that the Joint Venture will be owned initially 70% by Neovacs, with Stellar holding the remaining 30% interest. There can be no assurance that the Joint Venture will be consummated or, if consummated, will achieve the expected results.

Stellar is a leader in the sustainable manufacture of KLH, a carrier protein used for its immune-stimulating properties in the production of active immunotherapies (also known as conjugated therapeutic vaccines). KLH is a key component of Neovacs' Kinoid technology.

Neovacs is a leader in the development of active immunotherapies for autoimmune and inflammatory diseases. Neovacs' patented Kinoid technology combines a targeted cytokine attached to Stellar KLH™ as the immune-stimulating carrier molecule. Neovacs' lead product candidate IFNa-Kinoid for the treatment of systemic lupus erythematosus (lupus) is in Phase IIb clinical trials in Europe, Latin America and Asia. A Phase IIa trial in the United States is expected to begin in 2016. There can be no assurance that the clinical trials will ultimately lead to commercialization of the products.

"We look forward to working with Stellar Biotechnologies to form this cooperative venture, as they are the leading supplier of KLH protein based on sustainable, scalable aquaculture techniques," said Miguel Sieler, Chief Executive Officer of Neovacs. "Since KLH is a key component of IFNa-Kinoid, this venture is intended to support Neovacs as we work toward potential market launch, as well as bring added value in the field of KLH-Kinoid conjugate vaccines."





Friday, October 30, 2015

We're Moving




Thursday, October 29, 2015

Infamous guns at Auction

Two guns once owned by Bonnie and Clyde sold for over half a million dollars. Clyde Barrow's 1911 Colt .45-caliber automatic sold for $240,000.

Bonnie Parker's .38-caliber Detective Special that she had taped to her thigh when she was killed in a hail of gunfire in 1934 sold for $264,000 to the same bidder.

An online bidder paid $130,000 for a .45-caliber Tommy gun and $80,000 for an 1897 12-gauge shotgun that were seized from one of the duo's hideouts in Missouri in 1933.

Lawmen seized the weapons on April 13, 1933 after a bloody raid on an apartment in Joplin where the Barrow Gang were holed up. Two lawmen were killed while the gang escaped.

Al Capone’s Colt .25 semi-automatic pistol sold for over $ 16,000 in 2012.

His Colt .38 revolver sold for over $100,000 at a Christie's 2011 auction in London.
A gold-plated 7.65 Walther semi-automatic pistol with Hitler’s initials inlaid in gold on the ivory grips. It sold for $114,000 at a 1987 auction.

The pistol was taken by an American soldier during a dramatic attempt to capture or kill the dictator in Munich in the waning days of the war. Hitler was miles away in his bunker at the time.

John Dillinger's derringer, a miniature pistol that was found in the outlaw's sock when he was arrested in 1934 sold for $45,000.

The wooden gun Dillinger famously used to escape from the Crown Point, Indiana jail sold for $ 19,000.

A purse pistol Jesse James gave his wife, Zee, to commemorate the birth of their daughter sold for $20,000.

On October 5, 1892 five members of the Dalton Gang rode into the small town of Coffeyville, Kansas. After a failed bank robbery, the ensuing firefight killed four townspeople and four members of the Dalton Gang. $ 50,000.
Wyatt Earp's Colt .45-caliber revolver. $ 225,000. The revolver was passed down by the Earp family and is likely the one Wyatt used in the most legendary gunfight in wild west history, the O.K. Corral shootout — which became legend.

.44-caliber Smith & Wesson that killed Jesse James: $350,000. The James Gang terrorized Kansas and Missouri for nearly two decades led by the outlaw Jesse James.

The shot that killed James was delivered from a .44 which brought $350,000 at an Anaheim auction in 2003.
A tiny 6-inch derringer sitting in a display case at Ford’s Theatre National Historic Site is perhaps the most valuable in the world. Yet the only price ever paid for the item was around $25 in the mid-1800s, by John Wilkes Booth.

One shot was all Booth had to end Abraham Lincoln’s life when he entered the President’s theater box on April 14, 1865. Kept for generations as evidence by the War Department, the relic eventually returned to its fateful origins at the Ford Theatre where it had changed the course of history.